vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
RE/MAX Holdings, Inc. is the larger business by last-quarter revenue ($71.1M vs $37.2M, roughly 1.9× GYRE THERAPEUTICS, INC.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -3.7%, a 5.7% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -4.7%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
GYRE vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $71.1M |
| Net Profit | $-1.4M | $1.4M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 13.1% |
| Net Margin | -3.7% | 2.0% |
| Revenue YoY | 33.4% | -1.8% |
| Net Profit YoY | -340.1% | -75.2% |
| EPS (diluted) | $-0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $71.1M | ||
| Q3 25 | $30.6M | $73.2M | ||
| Q2 25 | $26.8M | $72.8M | ||
| Q1 25 | $22.1M | $74.5M | ||
| Q4 24 | $27.9M | $72.5M | ||
| Q3 24 | $25.5M | $78.5M | ||
| Q2 24 | $25.2M | $78.5M | ||
| Q1 24 | $27.2M | $78.3M |
| Q4 25 | $-1.4M | $1.4M | ||
| Q3 25 | $5.9M | $4.0M | ||
| Q2 25 | $1.6M | $4.7M | ||
| Q1 25 | $3.7M | $-2.0M | ||
| Q4 24 | $569.0K | $5.8M | ||
| Q3 24 | $2.9M | $966.0K | ||
| Q2 24 | $4.5M | $3.7M | ||
| Q1 24 | $9.9M | $-3.4M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 13.1% | ||
| Q3 25 | 22.7% | 25.0% | ||
| Q2 25 | 8.1% | 19.3% | ||
| Q1 25 | 10.3% | 7.2% | ||
| Q4 24 | 2.4% | 5.9% | ||
| Q3 24 | 16.6% | 19.4% | ||
| Q2 24 | 12.7% | 20.6% | ||
| Q1 24 | 29.7% | 5.8% |
| Q4 25 | -3.7% | 2.0% | ||
| Q3 25 | 19.4% | 5.4% | ||
| Q2 25 | 5.9% | 6.4% | ||
| Q1 25 | 16.9% | -2.6% | ||
| Q4 24 | 2.0% | 8.0% | ||
| Q3 24 | 11.2% | 1.2% | ||
| Q2 24 | 18.0% | 4.7% | ||
| Q1 24 | 36.6% | -4.3% |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $106.0M | $452.4M |
| Total Assets | $166.1M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $118.7M | ||
| Q3 25 | $60.0M | $107.5M | ||
| Q2 25 | $54.4M | $94.3M | ||
| Q1 25 | $29.9M | $89.1M | ||
| Q4 24 | $26.7M | $96.6M | ||
| Q3 24 | $25.1M | $83.8M | ||
| Q2 24 | $25.1M | $66.1M | ||
| Q1 24 | $37.4M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $106.0M | $452.4M | ||
| Q3 25 | $101.9M | $448.1M | ||
| Q2 25 | $92.0M | $442.4M | ||
| Q1 25 | $68.1M | $433.5M | ||
| Q4 24 | $63.3M | $429.5M | ||
| Q3 24 | $63.2M | $423.1M | ||
| Q2 24 | $60.4M | $418.4M | ||
| Q1 24 | $56.6M | $412.0M |
| Q4 25 | $166.1M | $582.5M | ||
| Q3 25 | $159.4M | $582.2M | ||
| Q2 25 | $152.6M | $574.8M | ||
| Q1 25 | $129.8M | $571.4M | ||
| Q4 24 | $125.4M | $581.6M | ||
| Q3 24 | $125.2M | $578.6M | ||
| Q2 24 | $120.9M | $571.4M | ||
| Q1 24 | $122.0M | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $40.9M |
| Free Cash FlowOCF − Capex | $-5.8M | $33.5M |
| FCF MarginFCF / Revenue | -15.5% | 47.1% |
| Capex IntensityCapex / Revenue | 0.4% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $40.9M | ||
| Q3 25 | $4.7M | $17.7M | ||
| Q2 25 | $2.1M | $4.6M | ||
| Q1 25 | $-129.0K | $5.7M | ||
| Q4 24 | $-2.8M | $59.7M | ||
| Q3 24 | $1.7M | $17.6M | ||
| Q2 24 | $-5.5M | $15.9M | ||
| Q1 24 | $2.9M | $9.4M |
| Q4 25 | $-5.8M | $33.5M | ||
| Q3 25 | $4.0M | $16.4M | ||
| Q2 25 | $1.8M | $2.9M | ||
| Q1 25 | $-251.0K | $4.0M | ||
| Q4 24 | $-2.8M | $53.0M | ||
| Q3 24 | $1.0M | $16.3M | ||
| Q2 24 | $-6.9M | $14.0M | ||
| Q1 24 | $2.7M | $6.8M |
| Q4 25 | -15.5% | 47.1% | ||
| Q3 25 | 13.1% | 22.4% | ||
| Q2 25 | 6.8% | 4.0% | ||
| Q1 25 | -1.1% | 5.3% | ||
| Q4 24 | -10.1% | 73.2% | ||
| Q3 24 | 4.1% | 20.8% | ||
| Q2 24 | -27.5% | 17.8% | ||
| Q1 24 | 9.8% | 8.6% |
| Q4 25 | 0.4% | 10.4% | ||
| Q3 25 | 2.2% | 1.8% | ||
| Q2 25 | 1.0% | 2.2% | ||
| Q1 25 | 0.6% | 2.3% | ||
| Q4 24 | 0.2% | 9.1% | ||
| Q3 24 | 2.7% | 1.7% | ||
| Q2 24 | 5.8% | 2.4% | ||
| Q1 24 | 0.9% | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | 0.79× | 4.45× | ||
| Q2 25 | 1.32× | 0.97× | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | 10.28× | ||
| Q3 24 | 0.60× | 18.22× | ||
| Q2 24 | -1.21× | 4.29× | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
